Baseline plasma-informed circulating tumor DNA analyses comparing multiplex digital PCR and NGS for longitudinal monitoring in Hodgkin lymphoma

Despite excellent cure rates in Hodgkin lymphoma (HL) [ 1 ], 10–15% of patients experience primary treatment failure or long-term treatment-associated complications due to overtreatment [ 2 , 3 ]. Currently, interim positron emission tomography–computed tomography (PET/CT) with 18 F-fluorodeoxyglucose, after two chemotherapy cycles, guides therapy in advanced stage-disease [ 4 ]. However, PET/CT has limited specificity, resulting in frequent false-positive and occasional false-negative findings [ 5 ]. underscoring the need for sensitive molecular tools for treatment response assessment and detection of measurable residual disease (MRD).

Authors

Institutions

Publication Details

Journal
Blood Cancer Journal
Published
2026-06-27
DOI
https://doi.org/10.1038/s41408-026-01555-2
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Baseline plasma-informed circulating tumor DNA analyses comparing multiplex digital PCR and NGS for longitudinal monitoring in Hodgkin lymphoma

Tove Wästerlid, Blaž Oder, Emma Tham, Richard Rosenquist et al.
Blood Cancer Journal
Lymphoma Diagnosis and Treatment
article

Baseline plasma-informed circulating tumor DNA analyses comparing multiplex digital PCR and NGS for longitudinal monitoring in Hodgkin lymphoma

Tove Wästerlid, Blaž Oder, Emma Tham, Richard Rosenquist, O. I. Krynina, Marzia Palma, Lotta Hansson, Irina Savitcheva, Anna Gellerbring, Mathias Johansson, Leonie Saft, Moa Hägglund, Z. Haider, Linn Deleskog Spångberg, Karl Nyrén, Karin E. Smedby, Cecilia Jylhä, Anna Lyander, Emil Lundin
article en

Abstract

Despite excellent cure rates in Hodgkin lymphoma (HL) [ 1 ], 10–15% of patients experience primary treatment failure or long-term treatment-associated complications due to overtreatment [ 2 , 3 ]. Currently, interim positron emission tomography–computed tomography (PET/CT) with 18 F-fluorodeoxyglucose, after two chemotherapy cycles, guides therapy in advanced stage-disease [ 4 ]. However, PET/CT has limited specificity, resulting in frequent false-positive and occasional false-negative findings [ 5 ]. underscoring the need for sensitive molecular tools for treatment response assessment and detection of measurable residual disease (MRD).

Blood Cancer JournalVol. 16(1)
Karolinska University Hospital (SE), Heidelberg University (DE), Science for Life Laboratory (SE), University Hospital Heidelberg (DE), Karolinska Institutet (SE), KTH Royal Institute of Technology (SE)
Cancerfonden, Karolinska Institutet, Kungliga Tekniska Högskolan, Vetenskapsrådet, Barncancerfonden, Radiumhemmets Forskningsfonder, Science for Life Laboratory
Good health and well-being
Openalex Percentile: Top 7%
Lymphoma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.